Publications by authors named "J V Kus"
Article Synopsis
- - An emerging fungal pathogen is causing a rise in difficult-to-treat dermatophytosis cases, especially in India, with some infections spreading globally, raising public health concerns.
- - In Ontario, Canada, there has been a notable increase in cases between 2014 and 2023, particularly affecting adults aged 20 to 64, and these cases are genetically similar to those found in other countries.
- - The majority of isolates in Ontario show resistance to terbinafine, a common treatment, highlighting the urgent need for better detection methods and public health awareness to control future outbreaks and treat infections effectively.
Medically important pathogenic fungi invade vertebrate tissue and are considered primary when part of their nature life cycle is associated with an animal host and are usually able to infect immunocompetent hosts. Opportunistic fungal pathogens complete their life cycle in environmental habitats or occur as commensals within or on the vertebrate body, but under certain conditions can thrive upon infecting humans. The extent of host damage in opportunistic infections largely depends on the portal and modality of entry as well as on the host's immune and metabolic status.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on invasive group A Streptococcus trends in Canada by analyzing emm1 isolates from 2018 to 2023.
- There was a notable rise in hypervirulent M1 lineage isolates, increasing from 22.1% to 60.2% during this period.
- Genomic analysis revealed clusters linked to specific locations and times, as well as genes tied to the acquisition of virulent bacteriophages.
Article Synopsis
- A new oral antiviral called nirmatrelvir-ritonavir (Paxlovid) was approved in Canada to combat COVID-19, but there are concerns about mutations in the M protein that could lead to resistance.
- A study analyzed over 93,000 M gene sequences from Ontario to assess the prevalence and trends of M mutations associated with nirmatrelvir resistance.
- Results indicated a slight decline in non-synonymous M mutations over time, with a very low incidence of resistant mutations, suggesting minimal widespread resistance to nirmatrelvir among Omicron variants in Ontario as of September 2023.